In a study published in , scientists investigated a protein called SYK (Spleen Tyrosine Kinase). They knew SYK was present in blood cancers but weren't sure exactly how it contributed to the disease. They discovered that SYK acts as a "partner in crime" with another protein called FLT3 , which is frequently mutated in leukemia patients. The 195RAR Mutation
SYK must physically touch FLT3 to activate it. 195rar
Because this specific interaction is so vital for the cancer to progress, it identified a new potential "weak spot" that future drugs could target to treat AML more effectively. In a study published in , scientists investigated
In scientific research, "195RAR" refers to a specific genetic mutation used to study how certain proteins interact within the body, particularly in the context of cancer development. The 195RAR Mutation SYK must physically touch FLT3
This tiny change—the mutation—acted like changing the shape of a key so it no longer fits a lock. What the Story Revealed
To prove that SYK was directly talking to FLT3, scientists needed to break the physical connection between them. They focused on a specific part of the SYK protein called the .
SYK Is a Critical Regulator of FLT3 in Acute Myeloid Leukemia